Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

Table 2 Dynamic fluctuation of CTCs in patients according to VEGFR status during follow-up

	CTC1 (baseline)	CTC2 (12 weeks)	CTC3 (24 weeks)	p (CTC1 vs CTC2)	p (CTC1 vs CTC3)	p (CTC1–CTC3)
Patients with CTCs (CTCs^CK+) N (%)	33 (42.8%)	18 (29%)	12 (18.2%)	0.088	0.005	0.015
Mean number of CTCs^CK+ (SD; range)	1.5 (1.5; 0–8)	1.7 (8.1; 0–64)	0.5 (1.5; 0–9)	0.019	0.003
Patients with CTCs^CK+VEGFR+) N (%)	23 (69.7%)	7 (38.9%)	5 (41.7%)	0.102	0.317	0.368
Mean number of CTCs^CK+VEGFR+ (SD; range)	1.4 (1.5; 0–5)	0.6 (1.05; 0–3)	0.5 (0.8; 0–2)	0.120	0.317

CTCs: circulating tumor cells; CK: cytokeratin; VEGFR: vascular endothelial growth factor receptor; SD: standard deviation; p: p value

ISSN: 1479-5876